9% in the placebo group for men with low-grade prostate cancer and 73
The finding that finasteride decreased the 7-year period prevalence of prostate cancer by 25% was actually very much in-line with our expectations
Androgens have been implicated in the development of prostate cancer
The study reported that finasteride prevents or delays the appearance of prostate cancer, thereby decreasing the overall incidence of prostate cancer
The Prostate Cancer Prevention Trial (PCPT) showed that prostate cancer risk is reduced by finasteride
3% of men (9060) who had completed the 7-year study, revealed that prostate cancer was detected in 803 (18